Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 136 participants.
Also called NCT03323476
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 136 participants
- Registry
-
NCT03323476
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT03323476. Randomized; no masking; primary purpose treatment. Start 2018-02-02 (actual); primary completion 2028-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
- Acronym
- MASTER-ANCA
- Condition
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Condition
- End Stage Renal Disease
- Intervention (Other)
- Discontinuation (or not initiation) of Immunosuppressive Therapy
- Intervention (Drug)
- Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
- Lead sponsor
- Centre Hospitalier Departemental Vendee
Record details
- Record id
cardio:ct-nct03323476- Content hash
af9deb92626d29a21ead4744549c28263c97d7199c6156fb4c7da52e3edddc47